Results 11 to 20 of about 40,253 (233)

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines [PDF]

, 2013
The potential clinical utility of genetic markers associated with response to fluoropyrimidine treatment in colorectal cancer patients remains controversial despite extensive study.
A Fariña-Sarasqueta, A Loganayagam, A Ruzzo, A Ruzzo, A Yawata, A Zaniboni, Andreas-Claudius Hoffmann, Ann Barrett, B Glimelius, BA Jennings, Barbara A. Jennings, C Fernandez-Rozadilla, C Zhang, CE de Bock, CF Thorn, D Caronia, Daniel Epurescu, DB Longley, E Hitre, E Van Cutsem, G Willis, Gavin S. Chu, Gavin Willis, H Gellekink, H Taflin, I Weisberg, J Cassidy, Jane Skinner, K Derwinger, K Kawakami, K Kawakami, L Peter, L Sharp, M Boisdron-Celle, M Gusella, M Scartozzi, M Schwab, M Vignoli, ME Fernández-Contreras, Melanie Keane, MJ Deenen, MS Braun, MV Mandola, MV Mandola, MV Mandola, N Horie, P Frosst, R Pullmann Jr., RA Goodwin, Richard Turner, S Afzal, S Afzal, S Kaneda, T André, TV Perneger, V Sulzyc-Bielicka, W Ichikawa, W Scheithauer, WG Johnson, Yoon K. Loke   +59 more
core   +7 more sources

Folic Acid and Leucovorin Have Potential to Prevent SARS-CoV-2-Virus Internalization by Interacting with S-Glycoprotein/Neuropilin-1 Receptor Complex

Molecules, 2023
The interaction of the SARS-CoV-2 spike (S) glycoprotein receptor-binding domain with the host-cell ACE2 receptor is a well-known step in virus infection. Neuropilin-1 (NRP-1) is another host factor involved in virus internalization.
Ranko Škrbić, Maja Travar, Miloš P. Stojiljković, Dragan M. Djuric, Relja Suručić   +4 more
doaj   +1 more source

Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis. [PDF]

, 2018
BackgroundContinuous-infusion 5-fluorouracil (5FU) and calcium leucovorin plus nab-paclitaxel and oxaliplatin have been shown to be active in patients with pancreatic cancer.
Bedford, Rudolph, Donahue, Timothy, Hines, O Joe, Hoos, William, Isacoff, William H, Rahib, Lola, Reber, Howard A, Upfill-Brown, Alexander   +7 more
core   +1 more source

Desmoplasia influenced recurrence of disease and mortality in stage III colorectal cancer within five years after surgery and adjuvant therapy

The Saudi Journal of Gastroenterology, 2017
Background/Aims: In patients with colon cancer who undergo resection for potential cure, 40–60% have advanced locoregional disease (stage III). Those who are suitable for adjuvant treatment had a definite disease-free-survival benefit.
Maddalena Zippi, Giorgio De Toma, Giovanni Minervini, Claudio Cassieri, Roberta Pica, Diodoro Colarusso, Simon Stock, Pietro Crispino   +7 more
doaj   +1 more source

A case of skin damage due to overdose methotrexate poisoning

Pifu-xingbing zhenliaoxue zazhi, 2022
We report a case of skin damage due to overdose methotrexate poisoning. A 74-year-old woman presented with erythema and desquamation of trunk and limbs accompanied with pain for 8 days.
Zhe ZHUANG, Fanghua LIU, Wencong XU, Ruitao ZOU, Jiao ZHANG, Bihui YU, Hongfang LIU, Yongfeng CHEN   +7 more
doaj   +1 more source

Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC) [PDF]

, 2013
Management of metastatic colorectal cancer requires a multimodal approach and must be performed by an experienced, multidisciplinary expert team. The optimal choice of the individual treatment modality, according to disease localization and extent, tumor
BASSO, ENRICO, CARUSO, DAVIDE, EVANGELISTA, SALVATORE, Foteini Vakiarou, G. Rinaldi, L. Bianchi, Lo Russo, Giuseppe, PAPA, ANSELMO, Perrone-congedi, Francesca, PRETE, ALESSANDRA ANNA, ROSSI, Luigi, SPINELLI, GIAN PAOLO, Stati, Valeria, TOMAO, SILVERIO, VERRICO, MONICA, ZORATTO, federica   +15 more
core   +1 more source

Forward Chemical Genetics in Yeast for Discovery of Chemical Probes Targeting Metabolism

Molecules, 2012
The many virtues that made the yeast Saccharomyces cerevisiae a dominant model organism for genetics and molecular biology, are now establishing its role in chemical genetics.
Marie Evangelista, Curt Scharfe, Ulrich Schlecht, Robert St.Onge   +3 more
doaj   +1 more source

Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors [PDF]

, 2019
Cetuximab and panitumumab are two distinct monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR), and both are widely used in combination with chemotherapy or as monotherapy to treat patients with RAS wild-type metastatic ...
Aderka, Dan, García Foncillas, Jesús, Ronga, Philippe, Stintzing, Sebastian, Sunakawa, Yu, Wainberg, Zev, Witzler, Pauline   +6 more
core   +1 more source

Duration of adjuvant chemotherapy for stage III colon cancer [PDF]

, 2018
BACKGROUND Since 2004, a regimen of 6 months of treatment with oxaliplatin plus a fluoropyrimidine has been standard adjuvant therapy in patients with stage III colon cancer.
Andre, Thierry, Boukovinas, Ioannis, Grothey, Axel, Iveson, Timothy, Kerr, Rachel, Labianca, Roberto, Meyerhardt, Jeffrey A., Meyers, Jeffrey P., Niedzwiecki, Donna, Paul, James, Renfro, Lindsay A., Sargent, Daniel J., Saunders, Mark, Shi, Qian, Shields, Anthony F., Sobrero, Alberto F., Souglakos, John, Taieb, Julien, Torri, Valter, Vernerey, Dewi, Watanabe, Toshiaki, Yamanaka, Takeharu, Yoshino, Takayuki   +22 more
core   +1 more source